SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Franklin D. Roosevelt

PatientFranklin D. Roosevelt
Date of birth1964-01-30
IdentifiersMRN HR-ET002-SYN; SSN (made up) 000-02-5130
Document date2026-04-10
AuthorNathaniel Brooks, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week heart failure medication safety check, echocardiogram, and cardiology review. [S]

History of Present Illness

Mr. Roosevelt returns two weeks after starting sacubitril/valsartan, carvedilol, empagliflozin, and furosemide for newly diagnosed heart failure. He is less breathless: he now propels his wheelchair the length of a long corridor before he has to rest, and he sleeps on two pillows without waking breathless. His leg swelling is less by evening. His home weights on a wheelchair scale have fallen by about 3 kg, and his home blood pressures run in the 140s over 80s. He has had no lightheadedness on transfers, no lip or tongue swelling, and no genital itching or urinary symptoms, and he has taken every dose. He still tires by late afternoon. He stopped smoking on his quit date last week and wears the nicotine patch every day; cravings come mostly in long meetings. He has had no muscle aches on atorvastatin. His echocardiogram and cardiology consultation were done this morning. [S]

ElementDetail
Interval changePropels a long corridor before resting; two pillows; less evening leg swelling
Weight logDown about 3 kg on the home wheelchair scale
Home blood pressure140s over 80s
Medication toleranceNo lightheadedness on transfers, angioedema, genital or urinary symptoms, or muscle aches
TobaccoNo cigarettes since his quit date last week; nicotine patch daily
NYHA classII to III, improved from III

Review of Systems

SystemResultFinding
ConstitutionalPositiveTires by late afternoon, less than before treatment; no fever
CardiovascularPositiveMild leg swelling by evening; sleeps on two pillows; no chest pain or palpitations
RespiratoryPositiveBreathless after propelling his wheelchair a long corridor; morning smoker's cough, less since he stopped smoking
GenitourinaryNegativeNo dysuria or genital itching
NeurologicalNegativeNo lightheadedness on transfers
MusculoskeletalNegativeNo muscle aches or cramps

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route2026-03-27 to 2026-04-10completedS
Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice dailyOne tablet by mouth twice dailyOral route2026-04-10activeS
Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route2026-03-27 to 2026-04-10completedS
Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with foodOne tablet by mouth twice daily with foodOral route2026-04-10 to 2026-06-26completedS
Spironolactone 25 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-10activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27activeS
Furosemide 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27 to 2026-06-26completedS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27activeS
Nicotine 21 mg/24 hr transdermal patch, apply one patch dailyApply one patch to the skin dailyTopical route2026-03-27 to 2026-06-26completedS
Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart750 mg intravenously, two doses one week apartIntravenous route2026-04-10 to 2026-04-17completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-10Body height188cmS
2026-04-10Body weight85kgS
2026-04-10Body mass index (BMI) [Ratio]24kg/m2S
2026-04-10Systolic blood pressure148mm[Hg]S
2026-04-10Diastolic blood pressure88mm[Hg]S
2026-04-10Heart rate84/minS
2026-04-10Respiratory rate18/minS
2026-04-10Body temperature36.8CelS
2026-04-10Oxygen saturation in Arterial blood by Pulse oximetry95%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-10Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
2026-04-10Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-04-10Creatinine [Mass/volume] in Serum or Plasma1.29mg/dL0.74-1.35 mg/dLNormalS
2026-04-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M63mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-10Glucose [Mass/volume] in Serum or Plasma98mg/dL70-99 mg/dLNormalS
2026-04-10Left ventricular Ejection fraction30%50-70%LowS

Physical Exam

Vital signs recorded on 2026-04-10; see the Vital Signs section. [S]

SystemFinding
GeneralAlert and comfortable at rest in his wheelchair; speaks in full sentences; weight 85 kg on the wheelchair scale, down 3 kg in two weeks
NeckJugular venous pressure 9 cm at 45 degrees
LungsFine crackles at both bases
HeartRegular rhythm, rate 84; S3; apical impulse displaced laterally
Extremities1+ symmetric edema at the ankles and shins

Problems

ProblemClinical statusVerificationCodeProvenance
Hypertensive heart disease with heart failure; synthetic modern diagnosis linked to the documented 1944 findingsactiveconfirmed I11.0S — Synthetic active diagnosis for the teaching episode; the 1944 findings remain D.
Heart failure with reduced ejection fraction, NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic diagnosis confirmed by echocardiogram in the modern episode.
Nicotine dependence, cigarettesactiveconfirmed F17.210S — Synthetic modern diagnosis linked to documented cigarette smoking.
Iron deficiency anemia in heart failure, repleted with intravenous ironresolvedconfirmed D50.9S — Synthetic finding that echoes the documented 1941 anemia; the modern values are S.
Paraplegia from a paralytic illness at age 39, historically diagnosed as poliomyelitis; cause retrospectively disputedactiveprovisional B91S — Synthetic modern coding of the documented diagnosis; the alternative cause remains R.
Prediabetesactiveconfirmed R73.03S — Synthetic finding from the baseline HbA1c.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBasic metabolic panel1 to 2 weeks after starting or changing sacubitril/valsartan, spironolactone, empagliflozin, or a diuretic; every 3 to 6 months when stableCompleted todayTwo weeks after starting sacubitril/valsartan, empagliflozin, and furosemide. Sodium 136, potassium 4.8, creatinine 1.29 mg/dL (up 9 percent), eGFR 63
LaboratoryBasic metabolic panel after today's changes1 to 2 weeks after titrating sacubitril/valsartan or starting spironolactoneDueBoth change today; to be drawn at the second iron infusion next week
ImagingTransthoracic echocardiogramAt diagnosis; repeat 3 to 6 months after therapy is optimized, or with unexplained changeCompleted todayEjection fraction 30 percent: heart failure with reduced ejection fraction. Repeat after tolerated doses are reached, to decide on device therapy
Imaging12-lead ECGAt initial evaluation; repeat with symptom change, arrhythmia, or device considerationDeferredNo ECG from the diagnostic workup is on file, a deviation from the protocol. Rhythm is regular on examination and no device decision is due yet, so no harm has resulted. Corrective action: obtain an ECG before the device decision that follows the repeat echocardiogram
LaboratoryLiver tests (initial workup; ALT before starting a statin)Once at diagnosisDeferredNo liver panel from the diagnostic visit is on file, a deviation from the heart failure and lipid protocols. He has no symptoms of liver injury. Routine liver monitoring on a statin is not recommended, so the corrective action is to test ALT only if symptoms appear
LaboratoryNT-proBNPAt diagnosis; selectively in outpatient follow-upNot indicated2850 pg/mL at diagnosis. Not used to titrate therapy; repeat at the three-month review to gauge decongestion
LaboratoryHemoglobin, ferritin, and transferrin saturationAt diagnosis; reassess 6 to 8 weeks after intravenous ironDueIron deficiency at diagnosis; intravenous iron starts today. The recheck is planned for the three-month review, about ten weeks after the second dose, to spare him an extra trip: a planned two-week departure from the anemia monograph's window
ReferralEndoscopy and colonoscopy for iron deficiency anemiaAt diagnosis of iron deficiency anemia in an adult manNot indicatedFerritin 48 ng/mL is above the 30 ng/mL threshold for absolute iron deficiency. His iron deficiency is the functional deficiency of heart failure, defined by a transferrin saturation below 20 percent. Routine colorectal cancer screening is still to be addressed
ExaminationBlood pressure, heart rate, weight, jugular venous pressure, edema, lungsEvery visit; every 1 to 2 weeks during titrationCompleted todayWeight down 3 kg; still mildly congested
SurveyNYHA functional classEvery visitCompleted todayClass II to III
SurveyKCCQ-12Baseline, then every 3 to 6 monthsUp to dateBaseline 38 two weeks ago; next at the three-month review
SurveyDepression screen (PHQ-2)PeriodicallyUp to dateScore 1 at diagnosis
ReferralCardiology consultationAt diagnosis, to confirm the diagnosis and guide titrationCompleted todaySeen today; agrees with the titration plan
ReferralCardiac rehabilitationEjection fraction 35 percent or less, NYHA II to IV, after 6 weeks of optimal therapyDueEligible by ejection fraction; reassess at the three-month review, once he has had six weeks of therapy
Medication safetyTolerance of sacubitril/valsartan, carvedilol, and empagliflozinEach visit while titratingCompleted todayNo hypotension, angioedema, bradycardia, volume depletion, or genital infection
Medication safetyPneumococcal vaccineOnce, for chronic heart disease and smokingCompleted todayPCV20 given today
Medication safetyTobacco use and cessation treatmentEvery visitCompleted todayAbstinent since his quit date last week; nicotine patch continued
LaboratoryLipid panel4 to 12 weeks after starting a statinDueAtorvastatin started two weeks ago
LaboratoryHbA1c, urine albumin-creatinine ratio, and TSHHbA1c and urine albumin yearly; TSH at diagnosisUp to dateHbA1c 5.9 percent, urine albumin-creatinine ratio 64 mg/g, and TSH 2.1 at diagnosis. The urine albumin test is repeated at the six-month review, because a single raised value can fall as blood pressure comes down
Self-managementHome blood pressure and daily weight log; low-sodium dietEvery visitCompleted todayLog reviewed; weights falling and blood pressures recorded twice daily

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026); Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021); USPSTF A and B Recommendations (2026)

Follow-up: Basic metabolic panel with the second iron infusion next week. Three-month heart failure and blood pressure review with laboratory tests and the KCCQ-12. Next scheduled visit 2026-06-26: three-month heart failure and blood pressure review. [S]